RNA Interference and Its Key Targets for Spinal Cord Injury Therapy: What Is Known So Far?
Open Access
- 10 October 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9861
Abstract
Spinal cord injury (SCI) is a neurological condition often resulting in permanent motor and sensory deficits, for which effective treatments remain limited. RNA interference (RNAi) is a post-transcriptional mechanism of the downregulation of gene expression mediated by small interfering RNAs. RNAi has demonstrated therapeutic efficacy in various neurological disorders, positioning it as a promising yet underexplored therapeutic strategy for SCI. Here, we provide a focused overview of the key pathological processes in SCI, including primary mechanical injury and secondary cascades such as inflammation, mitochondrial dysfunction, excitotoxicity, oxidative stress, multiple forms of cell death, and others. The potential of RNAi to selectively silence genes implicated in these pathological processes, thereby enhancing neuroprotection and functional recovery, is highlighted. We point out that not only protein-coding genes, but non-coding RNAs (ncRNAs) are suitable targets for RNAi. Novel RNAi tools such as CRISPR-Cas13 might revolutionize the field and offer new opportunities for SCI therapy. However, despite all these promising findings, relevant translational studies of RNAi remain scarce. Challenges related to delivery methods, long-term efficacy, and cell-specific targeting must be addressed. Importantly, combining RNAi with other strategies such as cell- or biomaterial-based therapies may enhance therapeutic outcomes. Future investigations should prioritize systematic comparisons of RNAi targets and delivery systems, ideally at single-cell resolution and in different SCI models, to identify the most relevant molecular pathways for clinical translation. Overall, RNAi represents a compelling but still underdeveloped approach for SCI therapy, requiring continued refinement to reach clinical application.Keywords
Funding Information
- FMBA of Russia (No. 075-15-2025-573)
This publication has 111 references indexed in Scilit:
- Two Faces of Chondroitin Sulfate Proteoglycan in Spinal Cord Repair: A Role in Microglia/Macrophage ActivationPLOS Medicine, 2008
- Transforming growth factor‐β1 regulates the fate of cultured spinal cord‐derived neural progenitor cellsCell Proliferation, 2008
- Inhibiting Glycosaminoglycan Chain Polymerization Decreases the Inhibitory Activity of Astrocyte-Derived Chondroitin Sulfate ProteoglycansJournal of Neuroscience, 2007
- RGMa inhibition promotes axonal growth and recovery after spinal cord injuryJournal of Cell Biology, 2006
- NGF-Induced Axon Growth Is Mediated by Localized Inactivation of GSK-3β and Functions of the Microtubule Plus End Binding Protein APCNeuron, 2004
- Ephrin-B2 and EphB2 Regulation of Astrocyte-Meningeal Fibroblast Interactions in Response to Spinal Cord Lesions in Adult RatsThe Journal of Neuroscience, 2003
- SOCS Proteins: Negative Regulators of Cytokine SignalingStem Cells, 2001
- Review of Current Evidence for Apoptosis After Spinal Cord InjuryJournal of Neurotrauma, 2000
- Axonal regrowth after spinal cord transection in adult zebrafishJournal of Comparative Neurology, 1997
- Apoptosis and delayed degeneration after spinal cord injury in rats and monkeysNature Medicine, 1997